Symptoms, Organ Involvement, and Warning Signs
At a Glance
PDGFRB-rearranged neoplasm may first appear on a blood test showing high white cells, eosinophils, or monocytes. It can enlarge the spleen or affect the heart, lungs, or skin. Chest pain, severe breathlessness, neurologic changes, or uncontrolled bleeding require emergency care.
Because this condition is driven by the overproduction of white blood cells, the symptoms you experience are often related to where those extra cells are congregating and whether they are causing inflammation. While some people have very few symptoms at diagnosis, others may experience issues ranging from mild fatigue to significant organ involvement.
Common Signs and Symptoms
In many cases, the first sign of a PDGFRB-rearranged neoplasm is an abnormality found on a routine blood test.
- High White Cell Counts: Most patients have an elevated white blood cell count. This often includes eosinophilia (too many eosinophils, a type of white blood cell) in about 58% to 80% of cases [1][2]. However, roughly 20% to 42% of patients do not have high eosinophil levels at diagnosis [1].
- Monocytosis: Some patients have an increase in monocytes, which can make the disease look like Chronic Myelomonocytic Leukemia (CMML) [2][1].
- Splenomegaly: An enlarged spleen is a frequent finding [3][4]. You might feel this as fullness in the upper left side of your abdomen or notice that you feel full quickly after eating only a small amount of food.
- General “Constitutional” Symptoms: Many patients report persistent fatigue, night sweats, unexplained weight loss, or a low-grade fever [3][5].
How Eosinophils Affect Organs
When eosinophil levels are very high, these cells can migrate into tissues and release toxic proteins that cause inflammation and scarring. This is known as extramedullary involvement—meaning the disease is active outside of the bone marrow [6][7].
- The Heart: This is the most serious area of potential involvement. Eosinophils can cause damage to the heart valves (especially the mitral valve) or the heart lining, leading to scarring or fluid buildup around the heart [6][8].
- The Lungs: High eosinophil counts can lead to “eosinophilic pneumonia” or inflammation in the lungs, causing a persistent cough or shortness of breath [7][9].
- The Skin: Some patients develop itchy rashes, raised bumps, or other skin lesions caused by eosinophil infiltration [10][5].
Watching for Progression
Most patients are diagnosed in a chronic phase, which is stable and responds well to treatment. However, the disease can sometimes progress to a more aggressive blast phase (similar to acute leukemia) or lymphoblastic lymphoma [1][11].
Signs that the disease may be changing include:
- Rapid Lymph Node Growth: Sudden swelling of lymph nodes in the neck, armpits, or groin [11].
- Bone Pain: Deep, aching pain in the long bones or ribs.
- New Bleeding or Bruising: This can happen if the cancer cells begin to “crowd out” the platelets in your bone marrow [12][13].
Red Flags: When to Seek Immediate Care
Most symptoms of this condition can be managed during routine appointments. However, because high eosinophil counts can cause rapid organ damage, you must be able to recognize emergency “red flag” symptoms.
Seek emergency evaluation (ER) immediately if you experience:
- Sudden Cardiac Distress: Chest pain, severe pressure in the chest, or a sudden, dramatic increase in shortness of breath (especially if you cannot catch your breath while resting) [6][8].
- Neurological Changes: Sudden weakness on one side of the body, drooping in the face, slurred speech, or a sudden change in vision. These can be signs of a blood clot or “mini-stroke” associated with high cell counts [8][14].
- Signs of Acute Blast Crisis: Extreme, sudden-onset exhaustion that makes it difficult to walk across a room, or heavy, uncontrollable bleeding (such as a nosebleed that won’t stop) [12][13].
Symptoms Requiring Same-Day or Routine Assessment:
New or worsening abdominal pain/fullness, sudden fever, or unusual bleeding require a prompt call to your hematology clinic for advice. Mild fatigue, a stable itchy rash, or a feeling of abdominal fullness that has been present for weeks without changing are generally not emergencies. These should be discussed with your hematologist at your next scheduled visit or via a routine phone call to the clinic. Please note that symptoms alone cannot diagnose disease progression; only your care team can determine if the disease is entering a new phase.
Common questions in this guide
What symptoms are common with a PDGFRB-rearranged neoplasm?
How can high eosinophils affect organs?
What can an enlarged spleen feel like?
Which symptoms require emergency care?
What could suggest the neoplasm is entering a blast phase?
Should I ask about heart testing if I have no heart symptoms?
Why might monocyte levels matter in this condition?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my absolute eosinophil count today, and how does it compare to my previous tests?
- 2.Given my diagnosis, do you recommend a baseline echocardiogram or cardiac MRI to check for silent heart involvement?
- 3.Are my current monocyte levels typical for this condition, or do they suggest a different pattern of disease?
- 4.Is my spleen enlargement something we need to monitor with imaging, or is physical exam enough?
- 5.What signs should I look for that might suggest the disease is moving from a 'chronic' phase to a 'blast' phase?
References
References (14)
- 1
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Jawhar M, Naumann N, Schwaab J, et al.
Annals of hematology 2017; (96(9)):1463-1470 doi:10.1007/s00277-017-3067-x.
PMID: 28725989 - 2
Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.
Fang H, Tang G, Loghavi S, et al.
Histopathology 2020; (76(7)):1042-1054 doi:10.1111/his.14097.
PMID: 32083752 - 3
MPRIP::PDGFRB Fusion Gene: A Rare Case Report of Adult Myeloid/Lymphoid Neoplasm With Eosinophilia and Tyrosine Kinase Gene Fusions.
Ukkahad T, Thamgrang T
Case reports in hematology 2025; (2025()):7098722 doi:10.1155/crh/7098722.
PMID: 40621131 - 4
CCDC88C::PDGFRB-rearranged myeloid neoplasm with predominant neutrophilia and rapid response to imatinib: a molecularly defined case report.
Guo Y, Wu H, Cai Z, et al.
Frontiers in oncology 2026; (16()):1855322 doi:10.3389/fonc.2026.1855322.
PMID: 42440560 - 5
Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports.
Wang SC, Yang WY
World journal of clinical cases 2021; (9(1)):204-210 doi:10.12998/wjcc.v9.i1.204.
PMID: 33511186 - 6
KCTD5::PDGFRB Fusion Gene Leading to Clonal Hypereosinophilia With Cardiac Involvement in a Young Adult: A Case Report.
de Groote L, Papazoglou D, Ku J, et al.
Case reports in hematology 2026; (2026()):6882482 doi:10.1155/crh/6882482.
PMID: 42602180 - 7
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N, Takahashi H, Naruse H, et al.
Molecular genetics & genomic medicine 2019; (7(4)):e00591 doi:10.1002/mgg3.591.
PMID: 30697976 - 8
Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.
Voeller J, DeNapoli T, Griffin TC
Cancer reports (Hoboken, N.J.) 2022; (5(11)):e1710 doi:10.1002/cnr2.1710.
PMID: 36241191 - 9
A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA.
Zanelli M, Smith M, Zizzo M, et al.
BMC pulmonary medicine 2019; (19(1)):216 doi:10.1186/s12890-019-0967-7.
PMID: 31744552 - 10
MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.
Gao M, Bachiashvili K, Jamy O, et al.
Annals of hematology 2026; (105(5)).
PMID: 42043473 - 11
Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene: A Rare Case of Poor Response to Imatinib and Possible Transformation Mechanisms from Myeloid Neoplasms of Bone Marrow to T-Cell Lymphoblastic Lymphoma Invasion in Lymph Nodes.
Gou Y, Tang Y, Liu S, et al.
Journal of inflammation research 2023; (16()):5163-5170 doi:10.2147/JIR.S427995.
PMID: 38026242 - 12
Resistance to imatinib in a ETV6::PDGFRB rearranged myeloid/lymphoid neoplasm with high-risk mutations: a case report.
Cavelier L, Saft L, Sander B, Deneberg S
Frontiers in oncology 2025; (15()):1611747 doi:10.3389/fonc.2025.1611747.
PMID: 41278291 - 13
Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusion.
Tripodi J, Tremblay D, Ahire D, Najfeld V
Molecular cytogenetics 2025; (18(1)):28 doi:10.1186/s13039-025-00730-7.
PMID: 41121250 - 14
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.
Luo R, Qi X
BMC neurology 2026; (26(1)).
PMID: 42135668
This page explains symptoms, organ involvement, and warning signs of PDGFRB-rearranged neoplasm for informational purposes only and does not replace medical advice. Contact your hematology team or seek emergency care for new or severe symptoms.